Kane Biotech Inc.
KNBIF
$0.02
$0.00-8.08%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -143.75% | -157.43% | -167.70% | 218.90% | 218.60% |
| Total Depreciation and Amortization | -26.95% | -11.61% | -12.61% | -11.40% | -9.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 100.68% | 105.12% | 107.39% | -501.27% | -541.46% |
| Change in Net Operating Assets | 12.39% | 49.91% | 51.74% | -305.40% | -244.58% |
| Cash from Operations | 22.82% | 35.13% | 41.03% | -95.51% | -95.61% |
| Capital Expenditure | 47.25% | 35.03% | 8.84% | -126.42% | -167.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -93.93% | -99.39% | -- | -- |
| Other Investing Activities | -115.51% | -129.64% | -107.01% | -129.13% | -5.53% |
| Cash from Investing | -100.49% | -99.98% | -100.55% | 364.13% | 1,341.56% |
| Total Debt Issued | -- | -- | 0.00% | -- | -- |
| Total Debt Repaid | 95.39% | 93.33% | 91.34% | -918.06% | -1,279.81% |
| Issuance of Common Stock | 421.19% | 1,069.16% | 660.03% | 398.46% | 49.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.52% | 93.89% | 93.60% | -1,082.98% | -822.18% |
| Cash from Financing | 148.83% | 143.17% | 152.67% | -763.44% | -451.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.60% | 135.57% | 559.91% | -267.38% | -292.05% |